PORTAGE BIOTECH INC (PRTG) Fundamental Analysis & Valuation

NASDAQ:PRTG • VGG7185A1369

Current stock price

6.81 USD
-0.15 (-2.16%)
At close:
7.4101 USD
+0.6 (+8.81%)
After Hours:

This PRTG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PRTG Profitability Analysis

1.1 Basic Checks

  • PRTG had negative earnings in the past year.
  • In the past year PRTG has reported a negative cash flow from operations.
  • In the past 5 years PRTG always reported negative net income.
  • PRTG had a negative operating cash flow in each of the past 5 years.
PRTG Yearly Net Income VS EBIT VS OCF VS FCFPRTG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

  • PRTG has a Return On Assets of -304.13%. This is amonst the worse of the industry: PRTG underperforms 93.54% of its industry peers.
Industry RankSector Rank
ROA -304.13%
ROE N/A
ROIC N/A
ROA(3y)-459.4%
ROA(5y)-279.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PRTG Yearly ROA, ROE, ROICPRTG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K 4K

1.3 Margins

  • PRTG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRTG Yearly Profit, Operating, Gross MarginsPRTG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. PRTG Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, PRTG has more shares outstanding
  • The number of shares outstanding for PRTG has been reduced compared to 5 years ago.
  • PRTG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRTG Yearly Shares OutstandingPRTG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
PRTG Yearly Total Debt VS Total AssetsPRTG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • PRTG has an Altman-Z score of -146.06. This is a bad value and indicates that PRTG is not financially healthy and even has some risk of bankruptcy.
  • PRTG has a worse Altman-Z score (-146.06) than 97.23% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -146.06
ROIC/WACCN/A
WACCN/A
PRTG Yearly LT Debt VS Equity VS FCFPRTG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 2.02 indicates that PRTG has no problem at all paying its short term obligations.
  • PRTG has a worse Current ratio (2.02) than 74.35% of its industry peers.
  • A Quick Ratio of 2.02 indicates that PRTG has no problem at all paying its short term obligations.
  • The Quick ratio of PRTG (2.02) is worse than 73.06% of its industry peers.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 2.02
PRTG Yearly Current Assets VS Current LiabilitesPRTG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. PRTG Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 92.66% over the past year.
EPS 1Y (TTM)92.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • PRTG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 62.98% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0%
EPS Next 2Y-68.71%
EPS Next 3Y-27.59%
EPS Next 5Y62.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRTG Yearly Revenue VS EstimatesPRTG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 50M 100M 150M 200M
PRTG Yearly EPS VS EstimatesPRTG Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. PRTG Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PRTG. In the last year negative earnings were reported.
  • Also next year PRTG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRTG Price Earnings VS Forward Price EarningsPRTG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRTG Per share dataPRTG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4 -5

4.3 Compensation for Growth

  • PRTG's earnings are expected to decrease with -27.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-68.71%
EPS Next 3Y-27.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PRTG Dividend Analysis

5.1 Amount

  • No dividends for PRTG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

PRTG Fundamentals: All Metrics, Ratios and Statistics

PORTAGE BIOTECH INC

NASDAQ:PRTG (9/3/2025, 8:00:01 PM)

After market: 7.4101 +0.6 (+8.81%)

6.81

-0.15 (-2.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)08-25
Earnings (Next)11-24
Inst Owners2.21%
Inst Owner Change0%
Ins Owners35.54%
Ins Owner ChangeN/A
Market Cap15.53M
Revenue(TTM)N/A
Net Income(TTM)-6.77M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.72
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.4
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -304.13%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-459.4%
ROA(5y)-279.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 2.02
Altman-Z -146.06
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.91%
EPS Next Y0%
EPS Next 2Y-68.71%
EPS Next 3Y-27.59%
EPS Next 5Y62.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y61.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.8%
OCF growth 3YN/A
OCF growth 5YN/A

PORTAGE BIOTECH INC / PRTG Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for PORTAGE BIOTECH INC?

ChartMill assigns a fundamental rating of 1 / 10 to PRTG.


What is the valuation status of PORTAGE BIOTECH INC (PRTG) stock?

ChartMill assigns a valuation rating of 0 / 10 to PORTAGE BIOTECH INC (PRTG). This can be considered as Overvalued.


Can you provide the profitability details for PORTAGE BIOTECH INC?

PORTAGE BIOTECH INC (PRTG) has a profitability rating of 0 / 10.


How financially healthy is PORTAGE BIOTECH INC?

The financial health rating of PORTAGE BIOTECH INC (PRTG) is 3 / 10.


Can you provide the expected EPS growth for PRTG stock?

The Earnings per Share (EPS) of PORTAGE BIOTECH INC (PRTG) is expected to decline by 0% in the next year.